Change over period: —
NSE · APLLTD
ALEM PHARMA
-1.2% from the 52-week high · +61.5% above the low
Alembic Pharmaceuticals Ltd. is a research and development pharmaceutical company, which engages in the research, development, manufacture, and market of generic and branded pharmaceutical products. The company is headquartered in Vadodara, Gujarat and currently employs 14,593 full-time employees. The company went IPO on 2011-09-17. The firm is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). The company delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. The company has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.
The short version. ALEM PHARMA reported revenue of ₹2,603 crore for Sep 2026, up 36.3% from a year earlier. Net profit was ₹335 crore (up 81.1% year on year). Return on equity was 11.9% in Mar 2026. Promoter holding was 69.87% in Sep 2026, up 0.26 points over 8 quarters.
1 · The price
How has the stock traded?
ALEM PHARMA trades 1.2% below its 52-week high and 61.5% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹2,603 cr.
Sep 2026 net profit of ₹335 cr.
3.2 pts higher than a year earlier.
Revenue compounded at 9.4% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2603 | 2150 | 1848 | 1876 | 1910 | 1711 | 1770 | 1693 |
| Net profit | 335 | 173 | 203 | 133 | 185 | 154 | 157 | 138 |
| Net margin % | 12.9 | 8.1 | 11.0 | 7.1 | 9.7 | 9.0 | 8.9 | 8.2 |
| EPS (₹) | 17.05 | 8.8 | 10.31 | 6.76 | 9.4 | 7.85 | 7.98 | 7.04 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7345 | 6672 | 6229 | 5653 | 5306 | 5393 | 4606 | 3935 |
| Net profit | 675 | 583 | 616 | 342 | 546 | 1178 | 829 | -1 |
| Net margin % | 9.2 | 8.7 | 9.9 | 6.1 | 10.3 | 21.8 | 18.0 | -0.0 |
| EPS (₹) | 34.33 | 29.68 | 31.33 | 17.4 | 27.76 | 59.94 | 43.97 | -0.06 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 11.9% in Mar 2026; debt to equity is 0.24.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 11.9 | 11.2 | 12.8 | 7.8 |
| Return on capital % | 12.8 | 14.6 | 13.8 | 9.6 |
| EBITDA margin % | 14.9 | 15.8 | 15.4 | 12.6 |
| Net margin % | 9.1 | 8.7 | 9.8 | 6.0 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 9.4% | 6.5% |
| Profit CAGR | 25.4% | -10.5% |
4 · The owners
Who holds it, and are they adding?
Up 0.26 pts over 8 quarters.
Up 0.38 pts over 8 quarters.
Down 0.63 pts over 8 quarters.
+2 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 69.61 | 69.67 | 69.67 | 69.74 | 69.74 | 69.74 | 69.87 | 69.87 | +0.26 |
| FII | 4.17 | 3.94 | 3.96 | 4.05 | 4.24 | 4.25 | 4.18 | 4.55 | +0.38 |
| DII | 16.06 | 16.43 | 16.46 | 16.3 | 16.17 | 16.18 | 15.94 | 15.43 | -0.63 |
| Public | 10.16 | 9.96 | 9.9 | 9.92 | 9.85 | 9.83 | 10.01 | 10.15 | -0.01 |
Mutual fund holdings · Oct 2026
32 schemes hold this stock
30 the month before.
- DSP Healthcare Fund3.09% of NAV
- ICICI Prudential Healthcare Fund2.33% of NAV
- UTI - Healthcare Fund1.78% of NAV
- The Wealth Company Mid cap fund1.65% of NAV
- Kotak Small Cap Fund1.53% of NAV
- Abakkus Small Cap Fund1.51% of NAV
- THE WEALTH COMPANY FLEXI CAP FUND1.44% of NAV
- UTI - MNC Fund1.25% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for ALEM PHARMA are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about ALEM PHARMA
What is the ALEM PHARMA share price?
ALEM PHARMA (APLLTD) last closed at ₹1,049.60, up 0.5% on the day. Its 52-week range is ₹646.55 to ₹1,057.10.
What is the market cap of ALEM PHARMA?
ALEM PHARMA has a market capitalisation of about ₹20,512 crore. Its price-to-earnings ratio is 24.5.
How are ALEM PHARMA's latest results?
ALEM PHARMA reported revenue of ₹2,603 crore for Sep 2026, up 36.3% from a year earlier. Net profit was ₹335 crore (up 81.1% year on year). Return on equity was 11.9% in Mar 2026. Promoter holding was 69.87% in Sep 2026, up 0.26 points over 8 quarters.
Who owns ALEM PHARMA?
As of Sep 2026, shareholding was: Promoter 69.87%, FII 4.55%, DII 15.43%, Public 10.15%.
How many mutual funds hold ALEM PHARMA?
32 mutual fund schemes held ALEM PHARMA in October 2026. That compares with 30 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 29 Jul 2025 · Final Dividend - Rs. 11
- 15 Jul 2024 · Final Dividend - Rs. 11
- 28 Jul 2023 · Final Dividend - Rs. 8
- 17 Aug 2022 · Interim Dividend - Rs. 10
- 19 Jul 2021 · Dividend - Rs. 14
- 16 Mar 2020 · Interim Dividend - Rs. 7
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.